Data regarding overdose of tafasitamab are unavailable. Symptoms of overdosage are likely to be consistent with its adverse effect profile, and may therefore involve significant infusion-related reactions and/or myelosuppression.L15292
Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies.L15302 It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19 antibodies.L15292,A191829
The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling.L15302 Its relative ubiquity across different stages of B-cell development, including pre-B and mature B-lymphocytes,L15292 as well as its presence in several B-cell malignancies (e.g. chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL))L15302 has made it a desirable target in the treatment these B-cell malignancies. Tafasatimab is designed to bind to and block the activity of the CD19 surface antigen, which ultimately results in the lysis of B-cells (both healthy and malignant).L15292
Having previously received Breakthrough Therapy, Fast Track, and Orphan designations from the FDA,A191829 tafasatimab-cxix (Monjuvi®) received an accelerated approval on July 31st, 2020, for the treatment of relapsed or refractory DLBCL in adult patients who cannot receive autologous stem cell transplants.L15307 It must be used in combination with lenalidomide, as this combination results in greater efficacy as compared to either agent alone.L15292
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Tafasitamab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Tafasitamab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Tafasitamab. |
| Estrone | Estrone may increase the thrombogenic activities of Tafasitamab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Tafasitamab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Tafasitamab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Tafasitamab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Tafasitamab. |
| Estriol | Estriol may increase the thrombogenic activities of Tafasitamab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Tafasitamab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Tafasitamab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Tafasitamab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Tafasitamab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Tafasitamab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Tafasitamab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Tafasitamab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Tafasitamab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Tafasitamab. |
| Equol | Equol may increase the thrombogenic activities of Tafasitamab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Tafasitamab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Tafasitamab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Tafasitamab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Tafasitamab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Tafasitamab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Tafasitamab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Tafasitamab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Tafasitamab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Tafasitamab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Tafasitamab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Tafasitamab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Tafasitamab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tafasitamab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Tafasitamab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Tafasitamab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Tafasitamab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tafasitamab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tafasitamab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Tafasitamab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tafasitamab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Tafasitamab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Tafasitamab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Tafasitamab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tafasitamab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tafasitamab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Tafasitamab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tafasitamab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tafasitamab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Tafasitamab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tafasitamab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Tafasitamab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Tafasitamab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Tafasitamab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tafasitamab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tafasitamab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Tafasitamab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Tafasitamab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Tafasitamab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Tafasitamab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Tafasitamab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Tafasitamab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Tafasitamab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Tafasitamab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Tafasitamab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Tafasitamab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Tafasitamab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Tafasitamab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Tafasitamab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Tafasitamab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Tafasitamab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Tafasitamab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Tafasitamab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Tafasitamab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Tafasitamab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Tafasitamab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Tafasitamab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Tafasitamab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Tafasitamab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Tafasitamab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Tafasitamab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Tafasitamab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Tafasitamab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Tafasitamab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Tafasitamab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Tafasitamab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Tafasitamab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Tafasitamab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Tafasitamab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tafasitamab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Tafasitamab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Tafasitamab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Tafasitamab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Tafasitamab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Tafasitamab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Tafasitamab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Tafasitamab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Tafasitamab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tafasitamab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Tafasitamab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Tafasitamab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Tafasitamab. |